Hims & Hers Forges Landmark Alliance with Novo Nordisk, Shares Surge

In a strategic pivot that reshapes its market position, telehealth provider Hims & Hers Health has entered a major collaboration with pharmaceutical giant Novo Nordisk. The announcement propelled the company’s stock to gain approximately 51% in a single week, marking its most significant trading surge on record.

A Strategic Realignment

The core of the agreement centers on distribution. Hims & Hers will begin offering Novo Nordisk’s flagship GLP-1 medications, Ozempic and Wegovy, on its platform later this month. The products will be available in both injectable and oral tablet forms. Concurrently, Hims & Hers will cease marketing its own compounded versions of these weight-loss and diabetes drugs, with existing patients being transitioned to the FDA-approved treatments.

This partnership resolves a legal dispute between the two companies. Novo Nordisk had filed a patent infringement lawsuit against the telehealth firm in February 2026, following Hims & Hers’ launch of a compounded oral version of Wegovy priced at $49. This legal action was formally withdrawn as part of the new deal. The collaboration follows a previously failed partnership attempt in Q2 2025, when Novo Nordisk accused Hims of selling compounded preparations under the guise of personalized medicine.

Operational Momentum Provides Foundation

The new alliance comes at a time of robust operational performance for Hims & Hers. The company reported full-year 2025 revenue of $2.35 billion, a 59% year-over-year increase. Its fourth-quarter revenue reached $617.8 million, exceeding consensus estimates. The subscriber base expanded to over 2.5 million users, generating a monthly average revenue per user of $83. A gross margin of 73.8% underscores an efficient cost structure.

Should investors sell immediately? Or is it worth buying Hims & Hers?

This financial strength has drawn positive analyst commentary. Barclays analyst Glen Santangelo raised his price target from $25 to $29, reaffirming an “Overweight” rating. Needham and Citi had also previously issued favorable assessments.

Challenges and Market Context

Despite the optimism, some headwinds persist. Hims & Hers concluded the fourth quarter with negative free cash flow and carries $1 billion in convertible notes. Capital expenditures more than doubled to roughly $243 million, driven largely by investments in pharmacy automation—a factor likely to pressure cash flow in the near term.

Following its multi-day rally, the stock experienced a predictable pullback, declining 7.9% to $23.84 on Thursday as investors took profits. Year-to-date, the shares remain down about 27%, a reflection of the regulatory uncertainty that had surrounded compounded GLP-1 drugs in preceding quarters.

The resolution of the legal conflict and secured access to Novo Nordisk’s core products signifies a fundamental shift for Hims & Hers. The company is moving from a potential market disruptor to an authorized distribution partner for one of the world’s largest pharmaceutical entities, redefining its role within the lucrative GLP-1 marketplace.